Compounded Semaglutide vs Compounded Tirzepatide: Vial, Dose, B12, and Cost Differences

Trust signals

> Reviewed by FormBlends Medical Team · Last updated May 2026 · 11 sources cited · Author: FormBlends Editorial

Key Takeaways

• Both are the same active molecules as their brand counterparts but prepared by state-licensed 503A compounding pharmacies rather than FDA-approved manufacturers.
• Compounded semaglutide is typically less expensive ($150-$300/month) than compounded tirzepatide ($250-$450/month).
• Compounded tirzepatide should produce more weight loss than compounded semaglutide, mirroring the brand-product head-to-head data.
• Both are usually delivered as multi-dose vials with syringes, not the prefilled pens used by brand products.
• Compounded versions are not FDA-approved and are not legally interchangeable with brand products under federal law.

Direct answer

Compounded semaglutide and compounded tirzepatide are the same active molecules as their brand counterparts, prepared by state-licensed 503A compounding pharmacies under specific regulatory circumstances. Both come as multi-dose vials with syringes. Compounded semaglutide costs less; compounded tirzepatide produces more weight loss. Neither is FDA-approved. The choice between them follows roughly the same logic as choosing between brand Wegovy and brand Zepbound, with the added consideration that compounded pricing brings tirzepatide closer to semaglutide's cost than the brand market does.

Table of contents

1. What "compounded" means in this context
2. The regulatory pathway after the shortage ended
3. Active ingredient sourcing and quality controls
4. Vial format vs pen format
5. Pricing comparison and what drives the gap
6. Dose flexibility and custom strengths
7. B12 and other combination formulations
8. Efficacy comparison: how brand trial data extrapolates
9. Side effects and tolerability differences
10. The contrary view: why some clinicians push back on compounded options
11. Decision logic for compounded patients
12. FAQ
13. Sources

What "compounded" means in this context

Compounding is the practice of a licensed pharmacist preparing a medication for a specific patient by combining, mixing, or altering ingredients in response to a prescription. It is a long-standing practice in pharmacy, especially for patients who need:

• Doses not commercially available
• Combinations of ingredients
• Allergen-free or preservative-free formulations
• Alternative routes of administration
• Medications that are commercially unavailable or in shortage

Two categories of compounding pharmacies exist under federal law:

	503A	503B
Regulator	State boards of pharmacy	FDA
Trigger for compounding	Individual patient prescription	Outsourcing for healthcare facilities
Volume	Patient-specific batches	Larger batch production
FDA registration	Not directly registered as a manufacturer	FDA-registered outsourcing facility
GMP compliance	State-level pharmacy standards	Current Good Manufacturing Practice required
Used by telehealth platforms	Yes, almost exclusively	Not for direct-to-patient sales

Legitimate compounded GLP-1 medications come from 503A pharmacies, not 503B. Any source representing itself otherwise should raise questions.

The regulatory pathway after the shortage ended

FDA placed semaglutide on the drug shortage list in 2022 and tirzepatide in 2022. Under U.S. compounding law, drugs in shortage can be compounded by 503A pharmacies without violating the "essentially a copy" restrictions that normally apply to compounding FDA-approved medications.

Status as of May 2026:

• Tirzepatide shortage declared resolved October 2024
• Semaglutide shortage declared resolved May 2025
• Both molecules removed from FDA shortage list
• Broad compounding under shortage rules no longer permitted

Legitimate compounded GLP-1 medications continue to be available, but under narrower circumstances:

• Personalized dose strengths the patient requires that are not commercially available
• Combinations with other active ingredients (semaglutide-B12 is the classic example)
• Documented medical reasons the FDA-approved product is unsuitable for the specific patient

The volume of compounded GLP-1 therapy has decreased substantially since 2024. The FDA has taken enforcement actions against pharmacies and platforms that continued to compound under expired shortage rules. Patients seeking compounded options today should verify the pharmacy is operating under one of the narrower permissible circumstances.

Active ingredient sourcing and quality controls

Compounded GLP-1 medications use active pharmaceutical ingredients (APIs) sourced from FDA-registered facilities. Common sources include API manufacturers in the United States, Europe, India, and China that hold FDA registration as bulk drug substance suppliers.

Quality control varies by 503A pharmacy. Well-run pharmacies typically include:

• Certificate of Analysis (CoA) verification for each API lot
• Independent third-party testing for identity, purity, and potency
• USP <797> compliance for sterile compounding
• Stability data for the specific formulations they produce
• State board of pharmacy oversight and routine inspection

Poorly run pharmacies may use unqualified APIs, lack proper sterility validation, or produce inconsistent dose accuracy. The FDA has issued warning letters to multiple compounding pharmacies operating during the GLP-1 shortage period over these concerns. Patient outcomes can vary between pharmacies even when the formulation on paper is identical.

Vial format vs pen format

Brand semaglutide and tirzepatide products use proprietary prefilled pen devices. The pen mechanics, dose-setting dials, and needle systems are patented. Compounding pharmacies do not have legal access to these patented delivery systems.

Compounded versions use generic multi-dose vials. The patient or caregiver:

1. Reconstitutes or draws the medication into a separate syringe
2. Sets the dose by syringe markings
3. Injects subcutaneously (abdomen, thigh, or upper arm)
4. Discards the syringe; the vial is preserved for next dose

Trade-offs vs pens:

Aspect	Brand pen	Compounded vial
Setup complexity	Low (twist, click, inject)	Higher (draw, measure, inject)
Dose precision	Fixed by pen mechanics	Depends on syringe reading
Sharps disposal	One per injection	One per injection (separate syringe)
Dose flexibility	Pen-defined strengths only	Any dose within vial range
Training required	Minimal	Brief orientation
Storage	Refrigeration; in-use stability per label	Refrigeration; multi-week stability typical

For patients comfortable with self-administered injections, vials are not significantly harder than pens after the first few weeks. For patients anxious about injections, the pen form factor is gentler.

Pricing comparison and what drives the gap

Product	Typical telehealth-compounded price range	Comparable brand cash price
Compounded semaglutide	$150-$300/month	Wegovy NovoCare: $499/month
Compounded tirzepatide	$250-$450/month	Zepbound vials: $349-$499/month (doses 2.5-10 mg); pen: ~$1,059/month
Compounded semaglutide + B12	$200-$350/month	Not available as brand
Compounded tirzepatide + B12	$300-$500/month	Not available as brand

Why tirzepatide costs more:

• API cost: tirzepatide is a longer peptide (39 amino acids vs 31) requiring more complex synthesis
• Lower production volume from API suppliers historically; this is changing
• Quality control complexity scales with peptide length
• Pharmacy markup conventions

The cost gap between compounded and brand has narrowed substantially in 2025-2026 because the Zepbound vial program ($349-$499/month) approaches compounded tirzepatide pricing at moderate doses. For self-pay patients at low/middle doses, the choice between compounded tirzepatide and Zepbound vials is more about preference and access than about cost.

Dose flexibility and custom strengths

A major clinical advantage of compounding is access to dose strengths not available in brand products.

Brand semaglutide strengths:

• Ozempic: 0.25, 0.5, 1, 2 mg/week
• Wegovy: 0.25, 0.5, 1, 1.7, 2.4 mg/week

Brand tirzepatide strengths:

• Mounjaro and Zepbound: 2.5, 5, 7.5, 10, 12.5, 15 mg/week

Compounded versions can be prepared at intermediate strengths the brand does not offer:

• Semaglutide: 0.375, 0.75, 1.5 mg (between standard doses)
• Tirzepatide: 3.75, 6.25, 8.75, 11.25 mg (between standard doses)

Clinical scenarios where intermediate dosing helps:

• Patient cannot tolerate the next titration step but plateaued on the current dose
• Patient experiences side effects on full dose but loses too little on half dose
• Patient wants to taper down rather than abruptly stop
• Patient is at goal weight and wants to minimize dose for maintenance

This dose flexibility is one of the most defensible reasons to choose compounded over brand, and one of the narrower circumstances under which compounding remains permissible after the shortage period.

B12 and other combination formulations

Combining semaglutide or tirzepatide with vitamin B12 is one of the most common compounded variations. The theoretical argument:

• GLP-1 agonists slow gastric emptying, which may reduce B12 absorption over time
• B12 plays roles in energy metabolism and red blood cell production
• Some patients report fatigue on GLP-1 therapy; B12 supplementation may help

The clinical evidence for the B12 combination specifically is limited. Most patients on GLP-1 therapy do not develop B12 deficiency over a 12-month treatment window. For patients with documented low B12 or with risk factors (vegetarianism, age, prior gastrointestinal surgery), supplementation is reasonable; whether it needs to be in the same vial as the GLP-1 is a separate question.

Other combinations that appear in compounded formulations:

• Glycine (purported anti-inflammatory and metabolic effects)
• NAD precursors (purported energy and longevity effects)
• L-carnitine (purported fat metabolism support)
• Amino acid blends

Evidence for these combinations is sparse to non-existent. Their presence in a compounded formulation should be questioned by the patient and clinician rather than assumed to add benefit.

Efficacy comparison: how brand trial data extrapolates

No clinical trial has directly compared compounded semaglutide to compounded tirzepatide. The brand trial data should extrapolate reasonably because the molecules are the same. Caveats:

• Compounded versions may have slight variations in API purity, fill volume accuracy, or stability that affect delivered dose
• Real-world adherence with vials may differ from pens (some patients find vials harder)
• Telehealth-based prescribing may produce less intensive lifestyle counseling than trial protocols

Expected outcomes if compounded versions deliver the same effective dose as brand:

Molecule	Expected weight loss at maintenance dose
Compounded semaglutide ~2 mg/week	~10-13% over 12 months (real-world, extrapolated from brand)
Compounded semaglutide ~2.4 mg/week	~12-15% over 12 months
Compounded tirzepatide ~10 mg/week	~15-18% over 12 months
Compounded tirzepatide ~15 mg/week	~18-22% over 12 months

The tirzepatide advantage of approximately 5-7 percentage points should hold, mirroring SURMOUNT-5. Real-world numbers run lower than trial means in both classes.

Side effects and tolerability differences

At equivalent active doses, side effect profiles match brand products:

• Nausea, vomiting, diarrhea, constipation
• Possible rare pancreatitis
• Possible gallbladder events
• Theoretical thyroid C-cell risk (FDA black-box on brand labels)

Compounded-specific concerns:

• Variability in dose delivered if syringe technique is poor
• Risk of injection-site infection if sterile technique is inadequate
• Theoretical risk of impurities if API quality is poor (well-run pharmacies test for this)
• No post-marketing safety surveillance specific to compounded formulations

Patient education matters more with vials than with pens. A patient who has been trained well on syringe technique and proper storage has minimal added risk; a patient who has not been trained well has meaningful added risk.

The contrary view: why some clinicians push back on compounded options

Argument 1: Brand vial pricing has narrowed the cost gap.

The Lilly Direct vial program for Zepbound ($349-$499/month) and NovoCare Direct for Wegovy ($499/month) approach compounded pricing for doses 2.5-10 mg tirzepatide and any-dose semaglutide. The financial argument for compounding is weaker than it was in 2023.

Argument 2: FDA approval status protects the patient.

FDA-approved products have undergone rigorous testing for safety, efficacy, consistency, and stability. Compounded products have not. For most patients, brand products are the more conservative choice when they are affordable.

Argument 3: Post-shortage regulatory environment is unstable.

The compounding pathway tightened in 2024-2025. Patients on compounded medications may find their supply disrupted if their pharmacy faces enforcement action. Brand products have more predictable supply continuity.

Argument 4: Dose flexibility is the only durable argument.

Of the historical reasons to compound (cost, dose flexibility, B12 combination, access during shortage), only dose flexibility and clinically justified combinations remain regulatorily defensible. Patients receiving standard doses for general weight loss may not have a legal basis for compounded prescriptions in 2026.

The counter: for patients without insurance coverage who need to manage cost, compounded options remain meaningfully cheaper than even the cash brand programs in some cases. The decision is patient-specific and requires honest assessment of the trade-offs.

Decision logic for compounded patients

Cost-driven and on standard dose: compare compounded options to Lilly Direct vials (for tirzepatide) or NovoCare Direct (for semaglutide). The cheapest path may be compounded; it may also be the brand cash program.

Need a non-standard dose: compounded versions are the only practical option. Brand products do not offer intermediate strengths.

Want maximum weight loss: compounded tirzepatide if cost permits, mirroring the SURMOUNT-5 finding.

Want lowest cost at modest efficacy: compounded semaglutide is the typical entry-point option.

Want maximum regulatory and safety assurance: brand products are the cleaner choice.

Have insurance that covers brand: use brand. Compounded options are not insurance-billable.

Have clinical contraindications to brand formulation (additives, preservatives): compounded options can be formulated without those components.

FAQ

What is compounded semaglutide vs tirzepatide? Same active molecules as the brand products, prepared by 503A pharmacies in response to individual prescriptions.

Are compounded versions equivalent to brand? The molecule may be identical but the regulatory pathway is different. Not FDA-approved. Not legally interchangeable.

Which is more effective for weight loss? Compounded tirzepatide, mirroring brand head-to-head data (SURMOUNT-5).

Cost difference? Compounded semaglutide typically $150-$300/month; compounded tirzepatide $250-$450/month.

Can they include B12? Yes. Common combination. Clinical evidence for added benefit is limited.

Pens or vials? Vials, with separate syringes. Brand pen formats are patented and not used in compounding.

Why do compounded versions still exist after the shortage? Under narrower circumstances: personalized doses, combinations, or documented medical need. Most pure shortage-rule compounding ended in 2024-2025.

Dosing schedules? Generally follow brand titration; some pharmacies offer intermediate strengths.

Are they legal? Yes, under 503A rules with valid prescriptions. Mass compounding to general public is not legal.

What about safety? Side effect profile mirrors brand. Variability in pharmacy quality is the major variable. Choose pharmacies with documented quality controls.

Can I switch between compounded and brand? Yes, with a new prescription. Insurance may stop covering if you switch to compounded.

Is FormBlends a compounding pharmacy? No. FormBlends is a telehealth platform that connects patients with independent licensed prescribers and U.S. compounding pharmacies. We do not manufacture or compound medication ourselves.

Sources

1. FDA. Drug Quality and Security Act Section 503A and 503B compounding regulations.
2. FDA. Drug Shortage List, semaglutide injection and tirzepatide injection. Status changes 2024-2025.
3. Aronne LJ et al. Tirzepatide as Compared with Semaglutide for the Treatment of Obesity: SURMOUNT-5. New England Journal of Medicine. 2025.
4. Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity: SURMOUNT-1. New England Journal of Medicine. 2022.
5. Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity: STEP 1. New England Journal of Medicine. 2021.
6. United States Pharmacopeia. USP General Chapter <797> Pharmaceutical Compounding: Sterile Preparations.
7. Alliance for Pharmacy Compounding. Industry best practices statement on GLP-1 compounding. 2024-2025.
8. FDA. Warning letters issued to compounding pharmacies regarding GLP-1 medications. 2023-2025.
9. Eli Lilly. Lilly Direct vial program for Zepbound. 2024 launch.
10. Novo Nordisk. NovoCare Direct program. 2024.
11. National Association of Boards of Pharmacy. Guidance on compounding GLP-1 receptor agonists. 2024-2025.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with independent licensed clinicians and U.S. state-licensed compounding pharmacies. We are not a manufacturer, prescriber, or dispensing pharmacy. Treatment is determined by your licensed clinician.

Compounded Medication Notice. Compounded semaglutide and compounded tirzepatide are not FDA-approved. They are not legally interchangeable with brand-name Wegovy, Ozempic, Zepbound, or Mounjaro. They are prepared by state-licensed 503A pharmacies in response to individual prescriptions and have not undergone FDA review for safety, efficacy, or manufacturing consistency. Quality control varies by pharmacy.

Results Disclaimer. Weight-loss outcomes referenced are extrapolated from brand-product clinical trials and may not match outcomes with compounded preparations. Real-world results depend on adherence, lifestyle, baseline metabolic health, dose, and the specific compounding pharmacy's product quality. Statements about expected outcomes are estimates, not guarantees.

Trademark Notice. Wegovy and Ozempic are registered trademarks of Novo Nordisk A/S. Zepbound and Mounjaro are registered trademarks of Eli Lilly and Company. Lilly Direct and NovoCare Direct are direct-to-patient programs from their respective owners. FormBlends does not claim any affiliation with Novo Nordisk, Eli Lilly, or any of their direct-to-patient programs.